Xbrane Biopharma AB · OMXSTO:XBRANE
Xbrane Biopharma AB — Q3 2022 Earnings Presentation
13 slides from Xbrane Biopharma AB's earnings presentation, Oct 28, 2022
Slide 1: Xbrane Biopharma AB Presentation Interim Report January – September 2022
Xbrane Biopharma AB Presentation Interim Report January — September 2022 "Positive opinion from CHMP* paves the way for the launch of Ximluci®" Martin Amark, CEO Solna October 28'", 2022 *) European Medicines Agency's (EMA‘s)committee for Medicinal Products for Human Use (CHMP} XBRANE science OR HIG
Slide 2: Disclaimer
Disclaimer ‘You must read the following before continuing, The following applies to this document and the information provided in this presentation by Xbrane Biopharma AB (publ) (the “Company” or any person on behalf of the Company and any other material distributed or statements made in connection
Slide 3: Xbrane has a portfolio addressing €53 billion of peak reference product sales
Xbrane has a portfolio addressing €53 billion of peak reference product sales Reference Commercialization Development Candidate Praslret Indication Next milestone Baviner H2 2022 : EU Age-related macular approval _ ~ C€ degeneration 2020/22 Q4 2022: Submission STADA LUCENTIS ° Diabetic macular edema
Slide 4: Ximluci pivotal phase III trial, regulatory process and launch timeline
2021 2022 2023 Ximluci® pivotal phase III trial Regulatory process EU Production launch volume (vial) Regulatory process US Jun 2021 Feb 2022 July 2022 Nov 2022 Q1 2023 Interim read-out Top-line data Lucentis® LoE EU EU Approval EU Launch Positive CHMP opinion announced 16 Sep 2022
Slide 5: European retinal VEGF inhibitor market STADA Ximluci launch readiness
European retinal VEGF inhibitor market STADA Ximluci launch readiness Europe retinal VEGF inhibitor market € million → 5000 4000 → Others 3000 → 2000 → 1000 0 2019 2022 → → → Source: IQVIA
Slide 6: September 2022 - Capital markets day key take aways
September 2022 - Capital markets day key take aways One out of four pure-play biosimilar developers in Europe Addressing fastest growing pharma market segment Purpose driven organization LY v > 4 9 Differentiated high yield / low cost production platform e® _——$_. eS... Validated by strong partnersh
Slide 7: Upcoming Capital Market Events
Upcoming Capital Market Events Jefferies Jefferies Healthcare Conference November 14-17th, 2022 London, UK YUBRANE Ss E FOR HIGH QUALITY BIOSIMILARS. NORDIC D) N B HEALTHCARE INFERENCE DNB Nordic Healthcare Conference December 15th, 2022 Oslo, Norway rane Biopharma Interim Report Januar
Slide 8: Ambition to be the most attractive employer within our field
Ambition to be the most attractive employer within our field Certified as a Great Place to Work® Equality Management team 59% vs 41% 50/50 No of employees +37% YoY 80 7A * 70 70 64 60 58 54 =Women ™Men =Women ™Men 50 40 International 45 Experience on 57% vs 43% Ao 35% PhD's 20 35 10 80 25 ) Q3'21 Q4
Slide 9: Slide 9
Slide 10: Company Expenses (G&A and R&D)
Company Expenses (G&A and R&D) Q3'21 a4'21 Qt '22 Q2'22 Q3 '22 Total Company Expenses have increased during the quarter 0 with 28% mainly as production preparations for the imminent launch of Ximluci®, planned for Q1, 2023, continues. -10 The expensed R&D costs for the quarter amounted to net of -20
Slide 11: Company Expenses (G&A and R&D)
Company Expenses (G&A and R&D) Q3'21 Q4'21 Q1'22 Q2 '22 10.4% Q3 '22 G&A R&D mintangible assets YUBRANE SCIENCE FOR HIGH QUALITY BIOSIMILARS. Comparing “like-for-like” year-on-year, the total Operating Costs have decreased by -10,4% The total R&D costs (incl. Intangible Asset of SEK 3.8m) amount to
Slide 12: Cash and Cash Equivalents, Shareholders' Equity
Cash and Cash Equivalents Shareholders’ Equity 450 500 —4ep4 383,4 450 431,7 400 396,3 350 400 365,7 301,5 200 295,2 350 326,8 250,1 oso 300 250 200 165,2 200 150 50 100 100 50 50 ) ) Q3'21 4121 1122, 222, 3122 Q3'24 424 Q'22,— 222, «3.122 At the end of the third quarter 2022, Cash amounted to 165.2
Slide 13: Q&A